Challenges with HBV Vaccination of High-Risk Adults: Advancing National & Local Infrastructure

Boatemaa Ntiri-Reid, JD, MPH
Director, Hepatitis

Overcoming Barriers to Adult Hepatitis B Vaccination
Virtual Briefing
April 30, 2020
The Hepatitis B Vaccination Pilot was a three year CDC-funded national program to reduce the incidence of acute hepatitis B virus (HBV) infection through the provision of expanded HBV vaccination for adults at increased risk of HBV infection or adults who presented for medical care in settings within or serving communities with increased incidence of acute hepatitis B.
Hepatitis B Vaccination Pilot

• The Pilot was part of a more than $35.5 million initiative by CDC, in 2012, to provide immunization capacity building assistance and strengthen the public health immunization infrastructure.

• Eligibility for funding under the initiative was limited to the 64 CDC-funded state and local health department immunization programs in the US.

• Program Area 7 of the initiative specifically focused on jurisdictions with an incidence of acute hepatitis B that is greater than or equal to 1.2 cases per 100,000 total population based on data from the 2010 National Notifiable Disease Surveillance System (NNDSS).
Hepatitis B Vaccination Pilot: Program Overview

- Award Total: $4,211,936
- No. Grantees: 14
- No. Doses of Vaccine: 161,171
- No. Settings: 459
- Geographic Distribution: 11 states, 3 cities
- Data collection: Multiple
Hepatitis B Vaccination Pilot: Key Settings

• In accordance with recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) settings where a high proportion of individuals had risk factors for HBV infection were prioritized. Specifically, adult HBV vaccination through the Pilot was provided in:
  • Correctional Facilities
  • Substance Use Treatment Facilities
  • Federally Qualified Health Centers
  • Health care facilities serving people who use drugs
  • Health care facilities serving gay, bisexual, and other men who have sex with men
  • HIV clinics
  • Local health department clinics
  • STD clinics
  • Other
Maryland’s Hepatitis B Vaccination Pilot: Demographics and Hepatitis B Epidemiology

- 5.8 million people
  - 53.9% White (non-Hispanic/Latinx)
  - 30% Black/African-American
  - 8.7% Hispanic/Latinx
  - 6.0% Asian
- 13.8% foreign-born
- 15-17% of adults uninsured
- 1.2 acute hepatitis B cases per 100,000 (2010)
Maryland’s Hepatitis B Vaccination Pilot: Program Overview

- Award Total: <$400,000
- No. Sub-grantees: 15 (10 LHDs, 5 CBOs)
- No. Doses of vaccine: 14,500
- No. Settings: 43
- Geographic distribution: 6 counties
- Data collection: ImmuNet
Maryland’s Hepatitis B Vaccination Pilot: Program Services

- Services to Partners
  - Vaccine
  - Training
  - Storage and handling procedures
  - Infrastructure development
  - Monitoring and data collection

- Partner Services
  - Outreach and HBV education
  - HBV screening
  - Vaccination
  - Linkage to care and treatment (where applicable)
Maryland’s Hepatitis B Vaccination Pilot: Key Settings

- The following settings were prioritized for expanded adult HBV vaccination in Maryland:
  - Correctional Facilities
  - Substance Use Treatment Facilities
  - Federally Qualified Health Centers
  - Health care facilities serving people who use drugs
  - Health care facilities serving gay, bisexual, and other men who have sex with men
  - HIV clinics
  - Local health department clinics
  - STD clinics
  - Other: CBOs and clinics that primarily serve Asian and African patients/clients
Maryland’s Hepatitis B Vaccination Pilot: Outcomes

• 10,014 doses of vaccine administered  
  • 35% second dose  
  • 22% third dose
• Approximately 3,486 doses administered after project close
• Comprehensive on-site training and ongoing technical assistance
• Culturally and linguistically appropriate community outreach and services
• Expanded infrastructure to support HBV vaccination in Maryland
Demographic Characteristics of Patients Administered Vaccine Doses, 2012–2015

HBV Vaccine Series Completion by Setting, 2012-2015

Key Takeaways

• Series completion is challenging, but possible
• Dedicated funding for adult HBV vaccination is critical
• Collaboration across healthcare, public health, and community is essential
Contact Information

Boatemaa Ntiri-Reid, JD, MPH
Director, Hepatitis
bntiri-reid@nastad.org

Hepatitis Team
hepatitis@nastad.org

For additional information about the CDC Hepatitis B Vaccination Pilot, visit: https://www.sciencedirect.com/science/article/pii/S0264410X19307467